Present invention discloses a stable composition of lutein and zeaxanthin and preparation method thereof. The disclosed composition comprises of free lutein, zeaxanthin as active pharmaceutical ingredients, carrier i.e., combination of olive oil and canola oil, marker compound i.e., oleocanthal derived from extra virgin olive oil and excipients preferably selected from tocopherol, thyme oil and ascorbyl palmitate. The resulting composition is highly stable and possesses a longer shelf life of about 6-12 months. It can be encapsulated preferably in soft-gel capsule form or in in the form of tablet or any other oral formulation including jelly, chewing gum, energy bar or patch form.
C07C 403/24 - Dérivés du cyclohexane ou d'un cyclohexène, comportant une chaîne latérale avec une partie non saturée d'au moins quatre atomes de carbone en ligne, ladite partie étant directement attachée aux cycles cyclohexane ou cyclohexène, p. ex. vitamine A, bêta-carotène, bêta-ionone ayant des chaînes latérales substituées par des cycles non aromatiques à six chaînons, p. ex. bêta-carotène
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Disinfectants; Fungicides; Herbicides; Dietetic preparations adapted for medical purposes; Food for babies; Material for stopping teeth, dental wax; Medical dressings; Medical plasters; Pharmaceutical preparations for the treatment of metabolic disorders, restoring cognitive health, managing diabetes, and rejuvenating the overall body homeostasis; Preparations for destroying vermin; Sanitary preparations for medical purposes
Gloriosa superbaG. superbaG. superba seeds using methanol, isolation of colchicine using non-polar solvent chloroform, isolation of colchicoside using n-butanol, removal of N-formyl impurity from colchicoside by using acid catalyst optimally hydroxylamine hydrochloride in methanol with traces of water optimally 1% water and further NMR spectroscopic analysis to detect the presence or absence of N-formyl impurity within the extracted pure product. By employing the method of present invention colchicoside of >90% purity is obtained.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
C07H 15/248 - Radicaux colchicine, p. ex. colchicosides
4.
A FORMULATION AND/OR COMBINATION TO PREVENT PULMONARY DISEASES INCLUDING SARS-COV-2
The present invention relates to a formulation to prevent pulmonary diseases associated with SARS-COV -2 infections, comprising fixed proportion of Quercetin, Ursolic Acid, and Ascorbic Acid (Vitamin-C), wherein the Quercetin Ursolic Acid, and Ascorbic Acid (Vitamin-C) are in a proportion of X:Y:Z where X,Y,Z may vary independent of each other from 0 to 15.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 31/375 - Acide ascorbique, c.-à-d. vitamine CSes sels
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
5.
HIGH PURITY ALPHA YOHIMBINE (RAUWOLSCINE) FROM RAUWOLFIA SPECIES
Present invention discloses a novel, commercially viable process for extraction of Alpha yohimbine from the bark, stem and leaves of Rauwolfia species. The extract is obtained by a precipitation method involving alternate steps of acidification and alkalization along with use of specific organic solvents. The extract gives higher yield of 7-8 fold as compared to other processes and without use of any column chromatography at all. Yield of alpha yohimbine from roots and leaves of Rauwolfia canescens by process of present invention was 0.017% and 0.4% respectively, indicating that leaves are a much better source. The HPLC analysis of the compound obtained indicated a purity of >90%.
C07D 459/00 - Composés hétérocycliques contenant des systèmes cycliques benz [g] indolo [2, 3-a] quinolizine, p. ex. yohimbineLeurs lactones en 16, 18, p. ex. lactone de l'acide réserpique
Rauwolfia Rauwolfia canescens Rauwolfia canescens by process of present invention was 0.017% and 0.4% respectively, indicating that leaves are a much better source. The HPLC analysis of the compound obtained indicated a purity of > 90%.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
7.
SINGLE HERB EXTRACT FOR THE TREATMENT OF PCOS (POLY CYSTIC OVARIAN SYNDROME)
The invention discloses a single herb extract for the treatment of PCOS (Poly Cystic Ovarian Syndrome) when given in oral dosage form as capsules of 500 mg, twice a day for period of time ranging from 30-90 days. The extract is obtained from fenugreek seeds using a specific method of extraction and comprises five furostanolicsaponins present in synergistic ratios as in Table 1 and having analytical profile as in Fig. 1.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses)CaesalpiniaceaeMimosaceaePapilionaceae
A novel extract from green coffee beans is disclosed which contains polyphenols and bioactive compounds e.g. Chlorogenic acids in a significantly higher concentration (70-80%) than in extracts of prior art methods (40-50%). The extract has greater ability to quench oxidative stress and destroy free radicals and offers health benefits due to its anti-obesity, anti-diabetic, anti-hypertensive, anti-tumor and anti-acid properties. The higher concentration of bioactive compounds has been achieved by use of polar solvents having polarity less than that of alcohols used for extraction viz. methanol or ethanol. The use of such solvents of lower polarity such as n-Butyl alcohol, ethyl acetate or acetone results in extraction of enriched Chlorogenic acid fractions into the extract, leaving polar impurities behind in aqueous medium. The extract obtained has significantly higher content of polyphenols and Chlorogenic acids ranging from 70-80% and a distinctive HPLC profile as shown in Fig. 2.
An improved process for the extraction of pygeum from the plant of the family rosacaea, amygdales tribe, genus Prunus species domestica (Indian Prunus) and related species (as herein defined) comprising the steps of collecting the plant material i.e. stem cuttings/ twigs, removing the leaves and drying till moisture content is about 10-15%, powdering the stem material, extracting with chlorinated organic solvents and water-alcohol mixture, in ratio of 1 :4, filtering and drying the extract under vacuum at 30 degree Celsius to obtain a greenish mass with bitter almond smell, the mass being referred to as 'pygeum' wherein in the improved process, a 'renewable plant source' i.e. stem cuttings/ twigs, are used for extraction of pygeum instead of a 'non-renewable' source such as bark of the tree. The pygeum obtained by the new process has a pharmacopeia profile similar to the product 'pygeum' obtained from a 'non- renewable source' i.e. bark of Pygeum africanum. Further, it is non-toxic and shows anti-BPH (benign prostatic hyperplasia) activity comparable with that of pygeum obtained from non-renewable source i.e. bark of Prunus Africana.
